APONTIS PHARMA
Pharmaceutical company focused on development, in-licensing and commercialization of combination 'Single Pill' medicines (2–3 off‑patent active ingredients) primarily for cardiovascular indications and selected respiratory products. Provides commercial services (marketing, co-promotion, licensing), pharmaceutical consultant/medical affairs support to physicians, market access activities and regulatory/pharmacovigilance functions. Emphasizes corporate governance, compliance and partnerships for evidence generation and healthcare research.
Industries
Nr. of Employees
medium (51-250)
APONTIS PHARMA
Monheim, North Rhine-Westphalia, Germany
Products
Portfolio of Single‑pill combination medicines
A portfolio of combination medicines (single tablets containing two to three active ingredients) targeting hypertension, dyslipidemia, cardiovascular secondary prophylaxis and selected respiratory indications.
Ramipril/Amlodipin/Atorvastatin
Triple-combination single pill containing ramipril, amlodipine, and atorvastatin for cardiovascular risk management.
Ramipril/Amlodipin/Hydrochlorothiazid
Triple-combination single pill containing ramipril, amlodipine, and hydrochlorothiazide for hypertension.
Acetylsalicylsäure/Atorvastatin/Ramipril
Triple fixed-dose combination polypill for secondary cardiovascular prevention.
Caramlo® Ator APONTIS®
Triple fixed-dose combination containing Candesartancilexetil, Amlodipin, and Atorvastatin.
RosuValsa APONTIS®
Fixed-dose combination containing Rosuvastatin and Valsartan.
Portfolio of Single‑pill combination medicines
A portfolio of combination medicines (single tablets containing two to three active ingredients) targeting hypertension, dyslipidemia, cardiovascular secondary prophylaxis and selected respiratory indications.
Ramipril/Amlodipin/Atorvastatin
Triple-combination single pill containing ramipril, amlodipine, and atorvastatin for cardiovascular risk management.
Ramipril/Amlodipin/Hydrochlorothiazid
Triple-combination single pill containing ramipril, amlodipine, and hydrochlorothiazide for hypertension.
Acetylsalicylsäure/Atorvastatin/Ramipril
Triple fixed-dose combination polypill for secondary cardiovascular prevention.
Caramlo® Ator APONTIS®
Triple fixed-dose combination containing Candesartancilexetil, Amlodipin, and Atorvastatin.
RosuValsa APONTIS®
Fixed-dose combination containing Rosuvastatin and Valsartan.
Services
Commercial partnership models including licensing, co‑promotion, fee‑for‑call and brand acquisition.
On‑site and digital consultancy and training for physicians and practice teams to support therapy implementation.
Market launch, promotion and sales operations for prescription medicines aimed at primary care and specialist prescribers.
Activities to demonstrate cost‑effectiveness and support reimbursement negotiations with payers.
Commercial partnership models including licensing, co‑promotion, fee‑for‑call and brand acquisition.
On‑site and digital consultancy and training for physicians and practice teams to support therapy implementation.
Market launch, promotion and sales operations for prescription medicines aimed at primary care and specialist prescribers.
Activities to demonstrate cost‑effectiveness and support reimbursement negotiations with payers.
Expertise Areas
- Single‑pill combination product development
- Cardiovascular therapeutics
- Commercialization and medical affairs
- Market access and health economics
Key Technologies
- Combination oral dosage formulation
- Inhalation device formulation
- Pharmacovigilance systems
- Real‑world evidence analysis
News & Updates
Company completed IPO in May 2021.
Company traces origins to a business founded in 1946 and highlights continuity of operations through acquisitions and reorganizations.
Since 2013 the company has launched multiple Single Pill products; stated target to expand to at least 20 market‑launched Single Pills by 2026.
Company completed IPO in May 2021.
Company traces origins to a business founded in 1946 and highlights continuity of operations through acquisitions and reorganizations.
Since 2013 the company has launched multiple Single Pill products; stated target to expand to at least 20 market‑launched Single Pills by 2026.